One hundred and seven consecutive patients presenting with significant peptic ulcer haemorrhage were randomised to endoscopic injection with 3-10 ml of 1:100000 adrenaline (55 patients, group 1) or to a combination of adrenaline and 5% ethanolamine (52 patients, group 2). All had major stigmata of haemorrhage and endoscopic injection was undertaken by a single endoscopist. The groups were well matched with regard to risk factors. Rebleeding occurred in eight of the group 1 patients and seven in the group 2 patients; surgical operation rates, median blood transfusion requirements, and hospital stay were similar in both groups. The efficacy of either form of injection was similar whether patients presented with active bleeding or a nonbleeding visible vessel. No complications occurred. In patients presenting with significant peptic ulcer bleeding, the addition of a sclerosant confers no advantage over injection with adrenaline alone.
The prognosis ofpatients presenting with significant bleeding from peptic ulcer is improved by endoscopic injection therapy, but the best injection regimen is unclear. Chung et al have shown that injection with 1:10000 adrenaline alone stops active bleeding in most cases, although rebleeding rates were not reported.' Wardehoff and Gros2 showed that injection of the sclerosant polidocanol reduces the risk of rebleeding in patients presenting with major stigmata of recent haemorrhage, but the efficacy of sclerosants alone as treatment for active bleeding is less clear. Other groups'5 have used combination injection therapy based upon the hypothesis that the vacoconstricting action of an initial adrenaline injection stops active bleeding and localises a subsequent sclerosant injection; because the effects of adrenaline will probably be short lived, a sclerosant is then injected to promote arterial thrombosis and prevent rebleeding.
In experimental animals an intramucosal injection of adrenaline effectively arrested active haemorrhage from gastric mucosal wounds, while various sclerosants actually exacerbated bleeding. 6 In the experimental situation, both 5% ethanolamine and ethanol injections induced a vigorous local inflammatory reaction associated with venous thrombosis, but endarteritis and arterial thrombosis were not seen. 6 Injections were given using a disposable 4 mm, 23 gauge injection needle (Keymed Ltd, Southend upon Sea, UK). Multiple injections (each of 0 5 to [ 5 ml) of 1:100 000 adrenaline were injected into and around the bleeding vessel to a total volume of 3-12 ml (median 7-5 ml). In patients randomised to group 2, a total of 0 2-2-0 ml 5% ethanolamine was then injected into the vessel. Our study included a selected subgroup of patients. The entry criteria defined high risk subjects, but the most severe cases comprising patients with very severe active haemorrhage in whom the bleeding site was not identified or not controlled by adrenaline injection were excluded. These patients can be considered to represent failures of adrenaline injection and it is conceivable that haemostasis could have been effected by the addition of a sclerosant injection. In four patients this was impossible because massive bleeding obscured the bleeding site and prevented injection; the diagnosis of peptic ulcer haemorrhage was made at surgical operation. In one patient active, arterial peptic ulcer bleeding was seen but the severity of bleeding and cardiovascular instability suggested that after a difficult, incomplete, and unsuccessful adrenaline injection a surgical operation represented the wisest treatment. The remaining failures of adrenaline injection were two subjects in whom inaccessibility due to anatomical deformity prevented injection. These failures do not detract from our conclusions, however, as the particular aim was to define the role of sclerosants in the prevention of rebleeding; there is little evidence that sclerosants have a role in acute haemostasis.
Our conclusions are at variance with the findings of some studies suggesting that small volumes of ethanol stop active peptic ulcer bleeding. IO-2 Most of these studies contain small numbers of patients or are uncontrolled, yet it is difficult to explain this trend in relation to our own findings. It is possible that the mechanism of haemostasis associated with ethanol (principally tissue dehydration) is different to that assumed for ethanolamine (endarteritis and thrombosis), but our own studies in experimental animals suggested that neither agent reliably caused arterial thrombosis.6 A further study also suggested that a combination of adrenaline and polidocanol was a more effective modality than adrenaline alone,'3 but the number of subjects was small and this trend did not achieve statistical significance.
In common with other published series, rebleeding rates were low in both study groups. As a result our study has limited power to detect a modest difference in efficacy between the two treatment regimens and our data do not unequivocally show that the addition of ethanolamine is of no clinical value. We can only state that if ethanolamine injection does confer additional benefit, this must be of extremely limited clinical value.
Our conclusions support the view of the group from Hong Kong' that injection therapy with dilute adrenaline leading to vasoconstriction possibly followed by arterial thrombosis is the most important therapeutic measure. Sclerosants should be avoided because they do not further reduce rebleeding rates and carry the risk of mucosal damage and ulcer complications. Our own policy is now to use 1:100 000 adrenaline without the addition of sclerosants as injection therapy for patients presenting with important endoscopic stigmata and peptic ulcer haemorrhage. 
